Tripartite Therapeutics Inc.

NT$6.61As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7920—

Country Taiwan

PE (Fwd) •••

TSR 10Y CAGR —

Div yield —

ROE —

—

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap —

ROIC —

SE Grade™

Value

Quality

Moat

Consensus

Reference

NT$8.45

27.81%

1894.31%

Hold 6|5|5|8|3

TTM

FYE 31 Dec TWD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

6.497

RevenueNT$B

4.978

5.101

5.232

5.456

5.663

5.909

6.107

6.260

6.650

6.893

6.818

4.01%

3.67%

22.15

Revenue growth%

25.92

23.42

26.20

25.09

24.48

22.83

21.63

23.30

23.91

25.08

24.41

23.30

24.19

24.46

Gross margin%

9.90

8.52

6.30

9.09

9.43

11.95

11.43

13.07

15.24

12.35

4.86

12.35

10.66

27.75

Operating margin%

12.83

14.36

16.40

14.76

12.80

15.12

14.22

16.55

17.36

20.36

3.68

16.55

14.94

7.07

Net margin%

7.74

7.07

5.68

2.76

5.16

5.25

8.22

7.29

9.36

8.33

8.64

8.22

7.18

32.35

P/E ratio (avg)x

17.21

16.63

17.11

16.09

17.40

16.47

18.30

17.33

18.87

17.99

6.545

17.99

17.27

26.90

EV/EBITx

20.59

21.42

25.60

26.69

29.78

31.82

35.18

35.77

36.18

41.27

35.75

35.77

30.80

5.15

FCF yield (avg)%

2.36

4.70

6.07

3.95

5.67

7.41

5.36

3.30

6.05

7.48

27.43

6.05

5.52

23.51

FCF margin%

29.06

26.07

27.23

26.03

27.48

28.46

26.63

26.98

24.68

22.18

3.21

26.63

26.80

1.235

FCF / Net incomex

0.779

0.679

0.619

0.551

0.501

0.496

0.526

0.528

0.537

0.499

0.135

0.526

0.532

19.47

ROIC%

23.14

25.55

24.43

25.85

26.28

25.68

26.62

27.63

29.29

28.44

19.70

27.63

26.06

23.32

Return on equity%

27.97

27.04

28.98

30.76

27.82

27.99

29.21

31.77

29.54

31.37

16.68

29.54

29.10

27.00

Return on assets%

21.50

23.13

22.23

21.21

24.00

21.17

19.58

17.93

17.63

20.23

19.31

19.58

21.19

0.55

EPSNT$

0.41

0.42

0.39

0.40

0.45

0.42

0.47

0.42

0.60

1.74%

0.24%

—

9.87

EPS growth%

9.80

10.93

8.32

8.96

11.32

12.17

11.79

11.94

9.64

7.26

12.33

11.79

10.37

0.17

Bookvalue per shNT$

0.48

0.50

0.52

0.57

0.55

0.49

0.44

0.39

0.55

(7.03%)

(3.10%)

—

0.22

FCF per shareNT$

0.35

0.34

0.38

0.41

0.46

0.52

0.49

0.51

0.55

0.53

0.38

2.93%

5.30%

—

0.45

Dividend per shNT$

0.58

0.57

0.65

0.69

0.66

0.70

0.77

0.85

0.92

0.97

0.48

7.98%

6.37%

—

26.37

Div yield (avg)%

11.76

14.34

16.97

19.73

16.90

18.53

20.51

19.38

19.68

22.16

9.65

19.68

18.96

9.53

Payout ratio%

14.67

16.16

15.98

18.86

17.59

16.69

18.37

16.81

19.07

21.67

28.29

18.37

17.20

113.1

Shares (diluted)M

133.7

151.8

147.2

156.0

170.1

172.3

191.5

207.4

241.6

280.8

114.7

10.55%

9.18%

6.61

Buyback yield%

14.24

17.24

17.38

20.05

20.28

19.94

17.85

18.95

21.61

20.26

22.77

19.94

19.45

0.529

D/E ratiox

1.648

1.748

1.737

1.900

2.228

2.565

2.868

3.135

3.378

3.908

1.218

3.135

2.396

7.514

Enterprise valueNT$B

7.732

7.852

7.812

7.502

8.309

7.738

7.747

8.635

9.320

10.01

8.583

3.81%

2.67%

7.873

LT debtNT$B

2.937

3.314

3.618

4.215

4.867

5.175

5.164

5.290

6.059

6.945

6.490

7.37%

9.44%

Peers (US$123.6M)

Cap (US$)

Obigen Pharma Inc.

187.8M

—

Uwell Biopharma, Inc.

147.5M

—

Pet Pharm Biotech Co.…

87.64M

96.97x

IMBiologics Corp.

124.0M

—

Capital

TTM

10Y

Leveragex

3.743

0.027

0.026

EBIT/Intx

1.538

0.538

0.514

Own earn%

(43.71)

(4.65)

16.19

Sh yield%

32.99

38.47

38.35

Owners

Insiders/Inst%

14.45

64.49

Short interest%

0.98

SBC / revenue%

0.64

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

13–20

$1 testx

—

Incr. ROIC%

Tripartite Therapeutics Inc. engages in the development of proprietary platform technologies for targeted delivery of therapeutics in Taiwan. Its proprietary OmniLink technology, helps in the therapeutic potential of active pharmaceutical ingredients that were previously limited by toxicities, in vivo stabilities, and unfavorable pharmacokinetic profiles.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

NT$6.893B

3.67%

1.00×

Cost of revenue

NT$3.984B

3.66%

1.00×

Operating expenses

NT$1.607B

3.70%

1.00×